SCHEMBL1354869

SCHEMBL1354869

CCC(Nc1nc(NCc2cccc(OC)c2N)c2ncn(C)c2n1)C(C)O

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 20/20 0.55
▸ CCNE1 P24864 13/20 0.55
▸ CDK7 P50613 11/20 0.55
▸ CDK9 P50750 11/20 0.55
▸ CCNH P51946 9/20 0.55
▸ CCNT1 O60563 5/20 0.55
▸ CDK5 Q00535 4/20 0.55
▸ CDK5R1 Q15078 2/20 0.55
▸ CDK1 P06493 9/20 0.54
▸ CDK4 P11802 9/20 0.54
▸ MAPK1 P28482 8/20 0.54
▸ CCNB1 P14635 7/20 0.54
▸ CCND1 P24385 6/20 0.54
▸ CCNT2 O60583 1/20 0.50
▸ CCNB2 O95067 1/20 0.50
▸ CCNE2 O96020 1/20 0.50
▸ CCNB3 Q8WWL7 1/20 0.50
▸ MNAT1 P51948 1/20 0.50
▸ CDK6 Q00534 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1355081 0.91 CDK2 (0.54) CDK2CCNE1CDK7CDK9CCNH
SCHEMBL1355329 0.91 CDK2 (0.67) CDK2CCNE1CDK7CDK9CCNH
SCHEMBL15117674 0.91 CDK2 (0.65) CDK2CCNE1CDK7CDK9CCNH
SCHEMBL1355296 0.89 CDK1 (0.57) CDK2CCNE1CDK7CDK9CCNH
SCHEMBL1354689 0.89 CDK2 (0.58) CDK2CCNE1CDK7CDK9CCNH
SCHEMBL1355135 0.87 CDK2 (0.57) CDK2CCNE1CDK7CDK9CCNH
SCHEMBL1354554 0.87 CDK2 (0.67) CDK2CCNE1CDK7CDK9CCNH
SCHEMBL1354173 0.86 CDK2 (0.51) CDK2CCNE1CDK7CDK9CCNH
SCHEMBL1352822 0.86 TDP1 (0.51) CDK2CCNE1CDK7CDK9CCNH
SCHEMBL1354578 0.86 CDK2 (0.61) CDK2CCNE1CDK7CDK9CCNH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9023857-B2 Substituted 6-(2-aminobenzylamino)purine derivatives, their use as medicaments and preparations containing these compounds UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2015-05-05 — — US disclosed
EP-2391626-B1 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS Univerzita Palackého v Olomouci (CZ) 2014-10-01 — — EP disclosed
EP-2391626-A2 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS Univerzita Palackého v Olomouci (CZ) 2011-12-07 — — EP disclosed
US-20110287111-A1 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2011-11-24 — — US disclosed
WO-2010085924-A2 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2010-08-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110287111-A1 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS CDK6, CCNI, CDK2 CDK2 3/4885CCNE1 55/4885CDK7 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback